𝔖 Bobbio Scriptorium

✦ LIBER ✦

475 Consistent progression-free survival benefit of capecitabine-bevacizumab in all prespecified subgroups of the RIBBON-1 study in patients with metastatic breast cancer (MBC)

✍ Scribed by J. O'Shaughnessy; V. Dieras; S. Chan

Book ID: 119601481
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 44 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)70496-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2101 ORAL Phase III study of ixabepilone

2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting

✍ J. Jassem; E. Thomas; H. Gomez; R.K. Li; H.C. Chung; L.E. Fein; V.F. Chan; R.A. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 76 KB

476 PFS by patient subgroup for standard

476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

✍ I. Bondarenko; J. Glaspy; A. Brufsky; O. Lipatov; E.A. Perez; S. Chan; X. Zou; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB